Suppr超能文献

尼日利亚北部耐多药结核病患者死亡的决定因素。

Determinants of mortality among patients with drug-resistant tuberculosis in northern Nigeria.

机构信息

KNCV/Challenge TB, Kano Regional Office, Kano, Nigeria.

Department of Medicine, Bayero University, Kano, Nigeria.

出版信息

PLoS One. 2019 Nov 19;14(11):e0225165. doi: 10.1371/journal.pone.0225165. eCollection 2019.

Abstract

BACKGROUND

Drug-Resistant tuberculosis (DR-TB) is estimated to cause about 10% of all TB related deaths. There is dearth of data on determinants of DR-TB mortality in Nigeria. Death among DR-TB treated cohorts in Nigeria from 2010 to 2013 was 30%, 29%, 15% and 13% respectively. Our objective was to identify factors affecting survival among DR-TB patients in northern Nigeria.

METHODS

Demographic and clinical data of all DR-TB patients enrolled in Kano, Katsina and Bauchi states of Nigeria between 1st February 2015 and 30th November 2016 was used. Survival analysis was done using Kaplan-Meier and multiple regression with Cox proportional hazard modeling.

RESULTS

Mean time to death during treatment is 19.2 weeks and 3.9 weeks among those awaiting treatment. Death was recorded among 38 of the 147 DR-TB patients assessed. HIV co-infection significantly increased probability of mortality, with an adjusted hazard ratio (aHR) of 2.35, 95% CI: 1.05-5.29, p = 0.038. Treatment delay showed significant negative association with survival (p = 0.000), not starting treatment significantly reduced probability of survival with an aHR of 7.98, 95% CI: 2.83-22.51, p = 0.000. Adjusted hazard ratios for patients started on treatment more than eight weeks after detection or within two to four weeks after detection, was beneficial though not statistically significant with respective p-values of 0.056 and 0.092. The model of care (facility vs. community-based) did not significantly influence survival.

CONCLUSION

Both HIV co-infected DR-TB patients and DR-TB patients that fail to start treatment immediately after diagnosis are at significant risk of mortality. Our study showed no significant difference in mortality based on models of care. The study highlights the need to address programmatic and operational issues pertaining to treatment delays and strengthening DR-TB/HIV co-management as key strategies to reduce mortality.

摘要

背景

耐多药结核病(DR-TB)据估计占所有结核病相关死亡的 10%左右。尼日利亚缺乏关于 DR-TB 死亡率决定因素的数据。2010 年至 2013 年,尼日利亚接受 DR-TB 治疗的队列中,分别有 30%、29%、15%和 13%的患者死亡。我们的目的是确定影响尼日利亚北部 DR-TB 患者生存的因素。

方法

使用 2015 年 2 月 1 日至 2016 年 11 月 30 日在尼日利亚卡诺、卡齐纳和包奇州登记的所有 DR-TB 患者的人口统计学和临床数据。使用 Kaplan-Meier 和 Cox 比例风险模型进行多变量回归进行生存分析。

结果

治疗期间的平均死亡时间为 19.2 周,等待治疗的患者为 3.9 周。在评估的 147 例 DR-TB 患者中,有 38 例死亡。HIV 合并感染显著增加了死亡率的可能性,调整后的危险比(aHR)为 2.35,95%可信区间:1.05-5.29,p=0.038。治疗延迟与生存呈显著负相关(p=0.000),未开始治疗显著降低了生存的可能性,aHR 为 7.98,95%可信区间:2.83-22.51,p=0.000。检测后 8 周以上或检测后 2-4 周开始治疗的患者的调整后的危险比虽然没有统计学意义,但分别为 0.056 和 0.092。治疗模式(医疗机构与社区为基础)对生存没有显著影响。

结论

HIV 合并感染的 DR-TB 患者和诊断后未能立即开始治疗的 DR-TB 患者均面临显著的死亡风险。我们的研究表明,基于治疗模式,死亡率没有显著差异。该研究强调需要解决与治疗延迟相关的方案和运营问题,并加强 DR-TB/HIV 联合管理,作为降低死亡率的关键策略。

相似文献

1
Determinants of mortality among patients with drug-resistant tuberculosis in northern Nigeria.
PLoS One. 2019 Nov 19;14(11):e0225165. doi: 10.1371/journal.pone.0225165. eCollection 2019.
2
Predictors of mortality among drug-resistant tuberculosis patients in Kaduna State, Nigeria.
Niger J Clin Pract. 2023 Jun;26(6):825-831. doi: 10.4103/njcp.njcp_734_22.
6
Treatment Outcomes of Children With HIV Infection and Drug-resistant TB in Three Provinces in South Africa, 2005-2008.
Pediatr Infect Dis J. 2017 Dec;36(12):e322-e327. doi: 10.1097/INF.0000000000001691.
7
Survival of smear-positive multidrug resistant tuberculosis patients in Witbank, South Africa: A retrospective cohort study.
Infect Dis (Lond). 2016;48(6):422-7. doi: 10.3109/23744235.2016.1153806. Epub 2016 Mar 8.
8
[Survival time and influencing factors in multidrug-resistant tuberculosis patients in Wuhan, 2006-2014].
Zhonghua Liu Xing Bing Xue Za Zhi. 2019 Nov 10;40(11):1409-1413. doi: 10.3760/cma.j.issn.0254-6450.2019.11.013.

引用本文的文献

3
Individual journeys to tuberculosis care in Nigeria's private sector during the COVID-19 pandemic.
BMJ Glob Health. 2024 Jan 9;9(1):e013124. doi: 10.1136/bmjgh-2023-013124.
4
Emerging threat of drug-resistant tuberculosis and trends in the era of COVID-19: A descriptive study from northwestern Nigeria.
J Clin Tuberc Other Mycobact Dis. 2022 May 17;28:100319. doi: 10.1016/j.jctube.2022.100319. eCollection 2022 Aug.
7
Strategies to Improve Antimicrobial Utilization with a Special Focus on Developing Countries.
Life (Basel). 2021 Jun 7;11(6):528. doi: 10.3390/life11060528.
8
Predictors of mortality in patients with drug-resistant tuberculosis: A systematic review and meta-analysis.
PLoS One. 2021 Jun 28;16(6):e0253848. doi: 10.1371/journal.pone.0253848. eCollection 2021.
10
Treatment delay in childhood pleural tuberculosis and associated factors.
BMC Infect Dis. 2020 Oct 27;20(1):793. doi: 10.1186/s12879-020-05496-4.

本文引用的文献

1
Predictors for Mortality among Multidrug-Resistant Tuberculosis Patients in Tanzania.
J Trop Med. 2017;2017:9241238. doi: 10.1155/2017/9241238. Epub 2017 Jul 20.
2
Survival of patients with multidrug-resistant TB in Eastern Europe: what makes a difference?
Thorax. 2016 Sep;71(9):854-61. doi: 10.1136/thoraxjnl-2015-207638. Epub 2016 Mar 24.
3
Survival of smear-positive multidrug resistant tuberculosis patients in Witbank, South Africa: A retrospective cohort study.
Infect Dis (Lond). 2016;48(6):422-7. doi: 10.3109/23744235.2016.1153806. Epub 2016 Mar 8.
5
Mortality among MDR-TB cases: comparison with drug-susceptible tuberculosis and associated factors.
PLoS One. 2015 Mar 19;10(3):e0119332. doi: 10.1371/journal.pone.0119332. eCollection 2015.
7
Risk factors for poor treatment outcomes in patients with MDR-TB and XDR-TB in China: retrospective multi-center investigation.
PLoS One. 2013 Dec 5;8(12):e82943. doi: 10.1371/journal.pone.0082943. eCollection 2013.
10
Survival of drug resistant tuberculosis patients in Lithuania: retrospective national cohort study.
BMJ Open. 2011 Nov 28;1(2):e000351. doi: 10.1136/bmjopen-2011-000351. Print 2011.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验